Global Biobanking Market Overview
According to SPER Market Research, the Global Biobanking Market is estimated to reach USD 112.18 billion by 2032 with a CAGR of 4.84%.
Gathering and conserving biological samples for use in research, biodiversity studies, and diagnostics are all parts of the biobanking process. Biobanks are necessary to assist biomedical research projects, offer individualised care, and maintain age demographic records. Technology-advanced market structures called "biobanking markets" are occupied with gathering and preserving biological data, materials, and samples for use in the future, as well as with learning more about various disorders, examining the effects of various diseases, and also with discovering a cure for them. The market is expected to expand as a result of the increase in the number of applications for biobank samples, which has created demand for the market for biobanking equipment. The amount of research projects and investments in R&D done by healthcare organisations have also increased, which has increased demand for the global market. Biobanking is not only expanding on its own; it is also enabling the dynamic expansion of its related markets. The cryogenic market is one such example, which is primarily in charge of giving these market companies storage facilities to preserve cells, tissues, blood, and other biological material.
Impact of COVID-19 on the Global Biobanking Market
The novel coronavirus, also known as Covid 19, has had a negative effect on the biobanking industry because of the risks involved with the storage, collection, and processing of human biospecimens and all biological materials due to the increased risk of virus and other infection transmission during this pandemic period. The ramifications of the SARS CoV-2 infection and subsequent transmission of the lethal virus have become a threat to the majority of biobanking companies. Various biobanking companies that were still collecting samples of human cells and tissues for cancer therapy have witnessed the consequences. On the other hand, a number of measures and resources have been employed to create low-level structures to collect SARS Cov-2 samples from a large base of population, to control the pandemic through the development of vaccines, and to provide a research base for all genomic studies and the development of healthcare systems.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Specimen Type, By Type of Biobank, By Ownership, By Application, By End User.
|
| Regions covered | Asia-Pacific, Europe, Middle East and Africa, North America, Latin America
|
| Companies Covered | BioIVT & Elevating Science, Geneticist Inc, Firalis S.A., AMS biotechnology Ltd. (AMSBIO LLC), and US Biolab Corporation, Inc., ProteoGenex, Inc., Cureline, Inc., Bay Biosciences LLC, CTI Biotech, and Boca Biolistics.
|
Global Biobanking Market Segmentation:
1. By Specimen Type:
- Blood Products
- Solid Tissue
- Cell Lines
- Nucleic Acid
- Others
2. By Type of Biobank:
- Population-based Biobanks
- Disease-oriented Biobanks
3. By Ownership:
- National/regional agency
- Non-profit Organization
- Universities
- Private Organization
4. By Application:
5. By End User:
- Academic Institutes
- Pharma & Biotech Companies
6. By Region:
- Asia-Pacific
- Europe
- Middle East
- Africa
- North America
- Latin America
Key Topics Covered in the Report:
- Size of Global Biobanking Market (FY’2019-FY’2032)
- Overview of Global Biobanking Market
- Segmentation of Global Biobanking Market By Specimen Type (Blood Products, Solid Tissue, Cell Lines, Nucleic Acid, and Others)
- Segmentation of Global Biobanking Market By Type of Biobank (Population-based Biobanks, and Disease-oriented Biobanks)
- Segmentation of Global Biobanking Market By Ownership (National/regional agency, Non-profit Organization, Universities, and Private Organization)
- Segmentation of Global Biobanking Market By Application (Therapeutics, Research)
- Segmentation of Global Biobanking Market By End User (Academic Institutes, Pharma & Biotech Companies)
- Statistical Snap of Global Biobanking Market
- Growth Analysis of Global Biobanking Market
- Problems and Challenges in Global Biobanking Market
- Competitive Landscape in the Global Biobanking Market
- Impact of COVID-19 and Demonetization on Global Biobanking Market
- Details on Recent Investment in Global Biobanking Market
- Competitive Analysis of Global Biobanking Market
- Major Players in the Global Biobanking Market
- SWOT Analysis of Global Biobanking Market
- Global Biobanking Market Future Outlook and Projections (FY’2019-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Biobanking Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Competitive Landscape
6.1 Global Biobanking Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Biobanking Market
7. Global Biobanking Market, By Specimen Type, 2019-2032 (USD Million)
7.1 Blood Products
7.2 Solid Tissue
7.3 Cell Lines
7.4 Nucleic Acid
7.5 Others
8. Global Biobanking Market, By Type of Biobank, 2019-2032 (USD Million)
8.1 Population-based Biobanks
8.2 Disease-oriented Biobanks
9. Global Biobanking Market, By Ownership, 2019-2032 (USD Million)
9.1 National/regional agency
9.2 Non-profit Organization
9.3 Universities
9.4 Private Organization
10. Global Biobanking Market, By Application, 2019-2032 (USD Million)
10.1 Therapeutics
10.2 Research
11. Global Biobanking Market, By End User, 2019-2032 (USD Million)
11.1 Academic Institutes
11.2 Pharma & Biotech Companies
12. Global Biobanking Market, By Region, 2019-2032 (USD Million)
12.1 Global Biobanking Market Size and Market Share by Region (2019-2025)
12.2 Global Biobanking Market Size and Market Share by Region (2026-2032)
12.3 Asia-Pacific
12.3.1 Australia
12.3.2 China
12.3.3 India
12.3.4 Japan
12.3.5 South Korea
12.3.6 Rest of Asia-Pacific
12.4 Europe
12.4.1 France
12.4.2 Germany
12.4.3 Italy
12.4.4 Spain
12.4.5 United Kingdom
12.4.6 Rest of Europe
12.5 Middle East and Africa
12.5.1 Kingdom of Saudi Arabia
12.5.2 United Arab Emirates
12.5.3 Rest of Middle East & Africa
12.6 North America
12.6.1 Canada
12.6.2 Mexico
12.6.3 United States
12.7 Latin America
12.7.1 Argentina
12.7.2 Brazil
12.7.3 Rest of Latin America
13.Company Profiles
13.1 AMS biotechnology Ltd (AMSBIO LLC)
13.1.1 Company details
13.1.2 Financial outlook
13.1.3 Product summary
13.1.4 Recent developments
13.2 Bay Biosciences LLC
13.2.1 Company details
13.2.2 Financial outlook
13.2.3 Product summary
13.2.4 Recent developments
13.3 BioIVT & Elevating Science
13.3.1 Company details
13.3.2 Financial outlook
13.3.3 Product summary
13.3.4 Recent developments
13.4 Boca Biolistics
13.4.1 Company details
13.4.2 Financial outlook
13.4.3 Product summary
13.4.4 Recent developments
13.5 CTI Biotech
13.5.1 Company details
13.5.2 Financial outlook
13.5.3 Product summary
13.5.4 Recent developments
13.6 Cureline, Inc
13.6.1 Company details
13.6.2 Financial outlook
13.6.3 Product summary
13.6.4 Recent developments
13.7 Firalis S.A.
13.7.1 Company details
13.7.2 Financial outlook
13.7.3 Product summary
13.7.4 Recent developments
13.8 Geneticist Inc
13.8.1 Company details
13.8.2 Financial outlook
13.8.3 Product summary
13.8.4 Recent developments
13.9 ProteoGenex, Inc
13.9.1 Company details
13.9.2 Financial outlook
13.9.3 Product summary
13.9.4 Recent developments
13.10 US Biolab Corporation, Inc
13.10.1 Company details
13.10.2 Financial outlook
13.10.3 Product summary
13.10.4 Recent developments
14.List of Abbreviations
15.Reference Links
16.Conclusion
17.Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
